GENMARK DIAGNOSTICS INC's ticker is GNMK and the CUSIP is 372309104. A total of 74 filers reported holding GENMARK DIAGNOSTICS INC in Q2 2013. The put-call ratio across all filers is 1.03 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $564,000 | +330.5% | 23,601 | +120.7% | 0.00% | – |
| Q4 2016 | $131,000 | +4.0% | 10,694 | +0.4% | 0.00% | – |
| Q3 2016 | $126,000 | +37.0% | 10,655 | -0.0% | 0.00% | – |
| Q2 2016 | $92,000 | +70.4% | 10,658 | +3.5% | 0.00% | – |
| Q1 2016 | $54,000 | -76.3% | 10,300 | -39.0% | 0.00% | -100.0% |
| Q2 2014 | $228,000 | +23.9% | 16,884 | -9.0% | 0.00% | 0.0% |
| Q1 2014 | $184,000 | -9.4% | 18,544 | +21.6% | 0.00% | 0.0% |
| Q4 2013 | $203,000 | +18.7% | 15,245 | +8.2% | 0.00% | 0.0% |
| Q3 2013 | $171,000 | +64.4% | 14,090 | +40.0% | 0.00% | – |
| Q2 2013 | $104,000 | – | 10,064 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEEDHAM INVESTMENT MANAGEMENT LLC | 1,443,400 | $5,947,000 | 1.68% |
| Casdin Capital, LLC | 3,365,000 | $13,864,000 | 1.47% |
| Lyon Street Capital, LLC | 191,656 | $790,000 | 1.26% |
| CADIAN CAPITAL MANAGEMENT, LP | 3,489,055 | $14,375,000 | 0.71% |
| Portolan Capital Management | 893,090 | $3,680,000 | 0.55% |
| Eversept Partners, LP | 524,257 | $2,159,939 | 0.54% |
| Bullseye Asset Management LLC | 78,961 | $325,000 | 0.39% |
| Parkman Healthcare Partners LLC | 200,000 | $824,000 | 0.38% |
| Granite Investment Partners, LLC | 757,878 | $3,122,000 | 0.20% |
| Bellevue Group AG | 2,411,926 | $9,937,000 | 0.19% |